The MYG1 Knockout 143B Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal population of human 143B osteosarcoma cells harboring a targeted disruption of the MYG1 gene. This polyclonal knockout model enables loss-of-function studies of MYG1 in a well-characterized cancer cell line without the need for monoclonal isolation, providing a robust tool for investigating mitochondrial biology and cancer metabolism.
The 143B cell line is a widely utilized human osteosarcoma model derived from a highly metastatic tumor, originally established from the HOS cell line. These cells retain the aggressive characteristics of osteosarcoma, including rapid proliferation, high tumorigenicity, and metastatic potential in vivo. They serve as a standard system for studying osteosarcoma biology, epithelial-mesenchymal transition, and metastasis. Their well-documented genetic and phenotypic properties make them an ideal host for creating knockout models to dissect the molecular mechanisms underlying cancer progression and therapeutic resistance.
MYG1 encodes a mitochondrial exoribonuclease that processes mitochondrial transcripts, a critical step for mitochondrial ribosome assembly and OXPHOS subunit translation. It functions downstream of NRF1, PGC-1??, and TFAM, and interacts with MRPL proteins and RNA processing enzymes. MYG1 directly matures MT-CO1 and MT-ND1 mRNAs. Disruption impairs ribosome assembly, OXPHOS subunit translation, ATP production, and oxidative phosphorylation. Additionally, MYG1 influences cell cycle progression, linking mitochondrial function to proliferation.
In 143B osteosarcoma cells, MYG1 knockout creates a loss-of-function model that disrupts mitochondrial translation and OXPHOS, which is particularly significant given the metabolic plasticity of cancer cells. The highly metastatic nature of 143B cells makes this knockout a valuable tool for examining how mitochondrial dysfunction impacts metastatic behavior and metabolic reprogramming. Since MYG1 is implicated in melanoma and osteosarcoma, this model aids in distinguishing the tissue-specific roles of mitochondrial gene expression in tumor progression. The resulting impairment of ATP production and cell proliferation provides a system to study metabolic vulnerabilities that could be exploited therapeutically.
This polyclonal MYG1 knockout cell population is ideally suited for a variety of downstream applications, including investigating mitochondrial translation in cancer, studying metabolic reprogramming in osteosarcoma, and screening for mitochondrial ribosome inhibitors. Researchers can employ this model for cell proliferation studies, drug sensitivity assays, and assessing the role of mitochondrial function in metastasis. Representative techniques include western blotting for OXPHOS complexes, RT-qPCR, Seahorse metabolic flux analysis, MTT proliferation assays, flow cytometry for apoptosis, and migration assays. By integrating these approaches, the MYG1 knockout 143B polyclonal cells provide a versatile platform for mechanistic studies and translational cancer research. For additional information or technical support, please contact Ascent Research.
